JY BioMed announces dual FDA Type II Drug Master File acceptance in January 2025, covering UC-MSC and UC-MSC-derived Exosomes. Establishing a fully traceable, vertically integrated regulatory platform, JY BioMed is advancing toward IND submission and positioning as an early leader in the exosome therapeutics space.